Company Information
CIN
Status
Date of Incorporation
30 July 1907
State / ROC
Ahmedabad / ROC Ahmedabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
10 August 2023
Paid Up Capital
513,563,656
Authorised Capital
600,000,000
Directors
Girish Srinivasiah Hirode
Director/Designated Partner
over 2 years ago
over 2 years ago
Kevalkumar B Thakkar
Manager/Secretary
over 2 years ago
over 2 years ago
Sameer Subhash Khera
Director/Designated Partner
over 2 years ago
over 2 years ago
Rati Desai
Director/Designated Partner
over 2 years ago
over 2 years ago
Drigesh Pramodbhai Mittal
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Rasesh Jayant Shah
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Mayank Natubhai Amin
Director/Designated Partner
about 6 years ago
about 6 years ago
Malika Chirayu Amin
Director/Designated Partner
almost 9 years ago
almost 9 years ago
Udit Chirayu Amin
Director/Designated Partner
almost 9 years ago
almost 9 years ago
Chandrashekhar Pundarikray Buch
Director/Designated Partner
about 12 years ago
about 12 years ago
Chirayu Ramanbhai Amin
Director/Designated Partner
over 14 years ago
over 14 years ago
Pranav Chirayu Amin
Wholetime Director
almost 19 years ago
almost 19 years ago
Paresh Manilal Saraiya
Casual Vacancy Director
almost 19 years ago
almost 19 years ago
Pranav Natverlal Parikh
Director
over 24 years ago
over 24 years ago
Past Directors
Abhijit Joshi
Additional Director
about 11 years ago
about 11 years ago
Rudradutt Chandrakant Saxena
Director
over 11 years ago
over 11 years ago
Ramanlal Maganlal Kapadia
Director
over 14 years ago
over 14 years ago
Chirag Kirtibhai Shukla
Company Secretary
over 14 years ago
over 14 years ago
Sanjay Sukhdevbhai Bhatt
Additional Director
over 14 years ago
over 14 years ago
Krishnapuram Gopalakrishnan Ramanathan
Director
over 22 years ago
over 22 years ago
Patents
A process of preparation of Rofecoxib Transdermal Gel comprising rhe following steps.
a. The thickening agent is dispersed in Purified Water.
b. The penetration enhancers and surfactants are mixed together.
c. The preservatives and Disodiun edetate are dissolved in Purified water.
d. Rofecoxib is incarporated ei...
Stabilized pharmaceutical compositions comprising pramipexole or pharmaceutically acceptable salts thereof and one or more dextrins and to method of preparation of the same. The said stabilized composition is in form of tablets comprising pramipexole dihydrochloride, β-cyclodextrin and one or more pharmaceutically a...
An (improved) process for the preparation of. (S)- 2,6-diamino-4,5,6,7-tetrahydro benzothiazole of formula II an intermediate compound for formation of Pramipexole of Formula (I) and its pharmaceutically acceptable salts, solvates
comprising the steps of
(a) reacting 4-amino cyclohexanol of formula (II...
A process of preparing tasteless micro encapsulated macrolides mainly comprising of the following steps:
a) dissolving the desired quantity of active drug and polymer taken in a ratio of 1:0.1 to 1:10, in an organic solvent/phase, such as Methylene Chloride, at room temperature, under continuous stirring to obtain ...
Novel compounds useful as reference makers for the analysis of Ropinirole hydrochloride of formula (Ia), pharmaceutical formulations therefor and method of testing the purity of a sample of Ropinirole hydrochloride or a pharmaceutical dosage form comprising Ropinirole hydrochloride.
A process for preparing nasal spray composition of loratidine and montelukast sodium comprises the following steps:
a. mixing 0.05-5% w/v loratidine in purified water to make a slurry;
b. adding 1M Hydrochloric acid under stirring to the slurry of step (a)
and continuing stirring until clear solution is obtained;...
The present invention relates to an improved Gel permeation chromatographic (GPC) method for the determination of average molecular weight of pentosan polysulfate sodium using dextran calibration standard.
The present invention provides a new polymorph Form T of Teriflunomide and a process for preparation thereof. The present invention provides a process for preparation of pure Teriflunomide.
An improved process for the manufacturing of Mexiletine Hydrochloride, by condensation of 2’, 6’-dimethylphenoxy with Chloroacetone in presences of polar aprotic solvent and a base to give the corresponding oxime, which is reduced to give Mexiletine base. This process also provides for producing the hydrochloride sa...
The present invention relates to an improved process for the preparation of 2-ethyl hexyl chloroformate (EHCF) & Benzyl Chloroformate (BCF) by reacting gaseous phosgene with thin film of liquid 2-ethyl hexanol or Benzyl Alcohol in Continuous Thin film Reactor (CTFR).
The present invention relates to extended release pharmaceutical compositions comprising desvenlafaxine base.
The present invention relates to process for the preparation of Amorphous Warfarin sodium.
The present invention relates to Cinacalcet tetrahydro; process for preparation thereof and processes for the use of Cinacalcet tetrahydro as reference marker and standard. This invention also relates to Cinacalcet salts having purity at least about 99 % wherein the content of Cinacalcet tetrahydro impurity is in th...
The present invention relates to an improved process for preparing Fesoterodine of formula (I).
The present invention relates to modified release formulations of Donepezil
Present invention relates to novel compound of formula (II) which is a useful reference marker for analysis of Roxithromycin of formula (I). Further it discloses method for analyzing purity of Roxithromycin samples for its formulation dosage forms.
A process for production of Astaxanthin pigment and particularly process for enhancing Astaxanthin content of cultures of genus Phaffia through mutagenesis.
The present invention provides improved process for the preparation of Deferasirox of formula (I).
The present invention relates to an improved process for the preparation of Erythromycin Estolate (I) which comprises i) treating erythromycin thiocyanate with a base in suitable solvent to obtain erythromycin base, ii) esterifying said erythromycin base with propionic anhydride in suitable solvent to obtain Erythro...
The present invention relates to controlled release multiple unit formulations, which comprise a water-insoluble inert core, an active ingredient and one or more pharmaceutically acceptable excipients. Further, the present invention relates to processes of preparing controlled release multiple unit formulations comp...
The present invention relates to provide a process for the preparation of (+)-(R)-Tolterodine-L-tartrate, comprises a step of aminating hydroxyl protected 3-(2-methoxy-5-methylphenyl)-3-phenyl propanol of formula (V) with diisopropylamine in the presence of water to obtain N, N-diisopropyl-3-(2-methoxy-5-methylpheny...
The present invention relates to extended release pharmaceutical composition comprising desvenlafaxine comprising one or more pH modifiers, atleast one release controlling agent and one or more other excipients. Further, the present invention relates to process of preparing extended release pharmaceutical compositio...
A process for the preparation of Pentosan polysulfate sodium comprising a step of purifying depolymerized crude Pentosan polysulfate sodium by filtration through NF membrane system.
DBU (0.1ml) was added to a stirred solution of 4,1’6’-trichloro-4,1’,6’-trideoxy galaactosucrose penta-acetate (TOPSA) (10g) in methanol (100ml) at ambient temperature (25-30˚C) and adjusted the pH of solution to 8 to 10 give clear solution. The reaction mixture was stirred at ambient temperature (25-30˚C) for 2 hou...
The present invention relates to a process for the preparation of Paliperidone of formula (I) and/or salts and esters thereof
The present invention relates to a process for the purification of Sucralose of formula (I) which comprises acetylation of substantially impure Sucralose to its penultimate intermediate 4,1’,6’-trichloro-4,1’,6’-trideoxy galactosucrose penta-acetate (TOPSA) of formula (VI) followed by purification of TOPSA and then ...
The present invention relates to a process for the preparation of Duloxetine hydrochloride of formula (I).
An improved process for the preparation of Candesartan cilexetil having purity of more than 99%. The improved process which comprises a step of cleaving the trityl group from tritylated Candesartan cilexetil of formula II is simple, easy to handle and feasible at commercial scale.
The present invention relates to a process for purification of Valsartan comprising steps of: (i) crystallizing from an organic solvent (ii) washing the crystallized product obtained in step (i) with a solvent selected from a group consisting of aliphatic hydrocarbon solvent.
The present invention relates to provide an improved process for the preparation of Clonidine hydrochloride comprising steps of:
(i) heating 2, 6-dichloroaniline with the mixture of acetic anhydride and formic acid to contain N-(2,6-dichlorophenyl)formamide
(ii) carrying out an one-pot reaction without isolating t...
The present invention relates to process for the preparation of Armodafinil comprising recycling unwanted (S)-(+)-isomer of 2-(benzhydrylsulfinyl) acetic acid.
A process for the preparation of N, N'-Disuccinimidyl carbonate (DSC) of formula
(I) comprising a step of reacting N-Hydroxysuccinimide (HOSu) of formula (II) with Phosgene or any compound capable of liberating phosgene in the presence of an organic solvent and in the absence of acid scavenger.
...
The present invention relates to an improved process for the preparation of Ropinirole hydrochloride of formula (Ia) comprising a step of carrying out hydrogenation in the presence of Pd/C and water as a solvent.
The present invention relates to an improved process for the preparation of Aripiprazole comprising a step of, reacting 7-hydroxy-tetrahydroquinolinone of formula (III) with 1,4-dibromobutane in the presence of base in dimethylacetamide to obtain 7-(4-bromobutoxy)-3,4-dihydrocarbostyril of formula (I) having purity ...
The present invention provides an improved process for the purification of Ropinirole hydrochloride of formula (Ia) comprising steps of: (i) dissolving Ropinirole hydrochloride in water; (ii) treating the solution obtained in step (i) with sodium dithionate and charcoal; (iii) treating the filtrate obtained in step ...
The present invention relates to an improved process for the preparation of 7-[4[-(2, 3-dichlorophenyl)-1-piperazinyl] butoxy] 3, 4-dihydro-2-(1H) quinolinone (Aripiprazole) having dimer impurity less than 0.15%, particularly, the present invention relates to an improved process for the preparation of 7-(4-chlorobut...
The present invention relates to the novel polymorphic forms of 7-[4-[4-(2,3-dichlorophenyl)piperazin-1,2,3,4-tetrahydroquinolin-2-one Form A, Form B, Form C and process for the preparation of same.
Extended release solid dosage forms of acetylcholinesterase inhibitors. More
particularly an extended release matrix tablet of galantamine comprising galantamine,
a water insoluble cellulose derivative, a water soluble binder and one or more release
retarding hydrophobic fusible components. A process for the p...
The present invention relates to an improved process for preparation of vinyl chloroformate (VCF) represented by a structural formula (I) as given below.
The present invention relates to an improved process for the preparation of Amorphous form of Atorvastatin Calcium of formula (I) employing conductive rotary vacuum dryers.
The claimed invention provides a novel methods of preparing Venlafaxine hydrochloride Form B. The process comprises the steps of dissolving any form of Venlafaxine hydrochloride either in water or in mixture of water and suitable solvent, azeotropically removing the water from said solution. It also comprises the st...
The present invention provides a process for the purification of Topiramate comprising treating Topiramate with aqueous alkali solution followed by washing the aqueous alkali solution of Toperamate with water immiscible sovent and neutralizing this solution to obtain Topiramate having purity at least 99% impurity of...
An extended release formulation comprising quetiapine or a pharmaceutically acceptable salt thereof and one or more non-gelling agents.
The present invention relates to a process for preparing Teriflunomide.
The invention relates to novel compound of formula (IV), which is an organic acid salt of N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine ester. This compound is an useful intermediate for process of preparation of Valsartan of formula (I), chemically known as (S)-N-(l-Carboxy-2-methylprop-l-yl)-N-pentanoyl-N-[2'-(1H-t...
The present invention relates to an anhydrous amorphous form of Imatinib mesylate and a process for preparation thereof.
The present invention provides a process for the preparation of 6-O-methylerythromycin A Form II comprising treating 6-O-methylerythromycin A with organic acid selected form trifluoroacetic acid, para-toluene sulphonic acid, oxalic acid or acetic acid and converting it into an organic salt of 6-O-methylerythromycin ...
The present invention relates to the novel process for preparation of Irbesartan of formula (I) by using the 2-(n-Butyl)-3-oxa-1-azaspiro [4.4] non-1-en-4-one of formula (II) with 4-aminomethyl-2’-cyanobiphenyl of formula (IIIa).
The present invention relates to an improved process for the preparation of Hydrochlorothiazide of formula (I) having purity of at least 99.9% and OVI content below detectable limit. The present invention further provides a new polymorphic form of Hydrochlorothiazide.
The present invention relates to a process for the preparation of an amorphous form of Candesartan cilexetil comprising steps of i) dissolving candesartan cilexetil in an organic solvent or optionally heating until it becomes clear solution ii) removing the solvent from the solution formed in step (i) by distillati...
The present invention relates to the one pot process for the preparation of 4,1’, 6’-trichloro-2, 3, 6,3’, 4’-penta-o-acetyl sucrose by detritylating 6, 1, 6’-tri-O-tritylsucrose penta-acetate with sulphonyl chloride selected from para-toluene sulphonyl chloride, methane sulphonyl chloride or ammonium chloride, unde...
An Improved Process for the Preparation of Alfuzosin and its novel polmorph.
The present invention relates to an improved process for the preparation of Alfuzosin of formula (I). The process involves utilizing intermediate of formula (la) wherein S represents acid residue of organic acids like acetic acid, oxalic a...
The present invention relates to an extended release pharmaceutical composition comprising quetiapine or pharmaceutically acceptable salts thereof and to process of preparing extended release compositions. The extended release pharmaceutical compositions are useful in providing therapeutically effective levels of qu...
The present invention relates to an improved process for the preparation of tritylated candesartan acid of formula (I)comprising a step of, reacting candesartan acid of formula (II)
The present invention relates to an improved process for the preparation of tritylated candesartan acid of formula (I) with trityl chl...
The present invention relates to an improved process for the preparation of Sucralose comprising a step of acetyl migration followed by isolation of 2,3,6,3",4"-Penta-0-acetylsucrose without addition of an antisolvent.
The following invention relates to process for preparing Cephalosporin intermediates of formula (I), wherein X is HI, HC1 or H2SO4, having high purity and yield and useful for synthesis of broad spectrum cephalosporin antibiotics.
The present invention relates to novel polymorphs of Telithromycin designated as from I, II and III and its process for preparation.Also it provides Telithromycin with at least 99% purity.
The present invention relates to an improved process for the preparation of 6,9-imino ether of formula (I) an intermediate used in preparation of Azithromycin. The present invention further provides a process for preparation of Azithromycin.
The present invention relates to an improved process for the preparation of Sucralose having purity of at least 99.6% comprising steps of (i) Dissolving substantially impure Sucralose in water (ii) Treating the solution obtained in step (i) with a partially water immiscible solvent (iii) Washing the said solvent pha...
The present invention relates to a process for the preparation of amorphous form of Rabeprazole sodium of formula (I).
The present invention relates to a continuous process for the preparation 6-amino penicillanic acid with the recovery of phenyl acetic acid comprising steps of:
a) enzymatic hydrolysis of Penicillin-G salt to 6-APA in continuous stirred tank reactor
b) passing a solution obtained in step (a) through plug flow rea...
The present invention relates to novel substantially amorphous Telithromycin and its process of preparation.
A process for the preparation of Irbesartan of formula (I) comprising the steps of: (i) reacting 4’ aminomethyl-2-cyano biphenyl of formula (VI) with 1-veleramido cyclopentane carboxylic acid of formula (V) in an organic solvent and in the presence of an acid, without activating the -COOH group of compound of formul...
The present invention relates to novel crystalline form of clonidine hydrochloride designated as form I comprising steps of: (i)refluxing charcoalized solution of crude Clonidine hydrochloride in methanol, (ii)filtering the solution obtain in step (i), (iii)removing methanol obtain in step (i), (iv) adding alcoholic...
The present invention relates to improved process for preparing Lovastatin of formula (I).
The present invention relates to provide a process for the preparation of Cefepime of formula (I) or its pharmaceutically acceptable salt comprising a step of reacting compound of formula (II) with compound of formula (III) In the presence of a base and base and dimethylformamide, optionally in presence of water.
...
The present invention relates to process for the prepatation of Aripiprazole form B having purity at least 99.5% and substantially free from dimer impurity, coprises the steps of
ix)dissolving aripiprozle in 25 volume of ethanol with 10% activated carbon
x)heating reaction mixture obtain in step(i) to reflux for 5...
Present invention relates to an improved process for the purification of Levetiracetam of formula (I) comprising (i) treating substantially impure Levetiracetam with acetic acid and activated carbon in a suitable organic solvent; (ii) stirring anf filtering the mixture obtained in step (i); (iii) evaporating the fil...
The present invention relates to an extended release once daily pharmaceutical formulation comprising venlafaxine hydrochloride and pharmaceutically acceptable excipients. More particularly, the present invention relates to an extended release composition in the form of mini-tablets which are incorporated in hard ge...
The present invention relates to an improved process for the preparation of Entacapone of formula (I) comprising a step of, condensation of 3, 4-dihydroxy-5- nitrobenzaldehyde of formula (II) with N, N-diethylcyanoacetamide of formula (III) in the presence of two component solvent system, a catalyst and optionally a...
The present invention relates to an improved process for preparation of 3-isopropyl-4-methoxyphenol represented by a structural formula (I) as given below.
The present invention relates to provide an improved process for the preparation of highly pure polymorphic from A of Entacapone with no individual impurity including Z-isomer of Entacapone less than 0.1%.
The present invention provides a new polymorph Form IV of Lamotrigine and a process for preparation thereof.
The present relates to use of high shear mixer technology application in 3, 4-Trichlorocarbanalide production to over come mass transfer limitation followed by reactive drying to drastically reduce the reaction time and increase throughput without compromising quality of product. The system comprise of high shear mi...
The present invention relates to provide an improved process for preparation of an amorphous form of Pentosan polysulfate sodium, comprising steps of:i)dissolving crude Pentosan polysulfate sodium having molecular weight of 4000 to 6000 Dalton in water ii)spray drying the solution obtained in step (i) to obtain amor...
The present invention relates to a process for preparing Quetiapine fumarate.
The present invention relates to an improved process for preparation of L-2,2’-anhydro-1(β-L-arabino furanosyl)thymine (I)
The present invention further provides an isolation procedure for of L-2,2’-anhydro-1(β-L-arabino furanosyl)thymine (I) form the reaction mixture. The present invention also provides novel poly...
An extended release pharmaceutical composition comprising pramipexole having an extended release profile such that not less than 25% of the total amount of pramipexole or a pharmaceutically acceptable salt thereof in the composition is released within one hourno,significant release of drug takes place over the subse...
The present invention relates to an improved process for preparing Quetiapine fumarate .
The present invention relates to an improved process for the preparation of 1-bromo-3,5-dimethyl adamantane of formula (III), which is an useful intermediate for synthesis of 1-amino-3,5-dimethyl adamantane of formula (I) or pharmaceutically acceptable salt thereof.
The present invention relates to an improved process for the preparation of choline salt of fenofibric acid corresponding to formula (I). The present invention also provides crystalline polymorphic form of choline salt of fenofibric acid corresponding to formula (I) designated as form A.
The present invention relates to an improved process for preparing Leflunomide of formula (I).
An extended release formulation comprising quetiapine or a pharmaceutical^ acceptable salt thereof, and a controlled release matrix comprising a mixture of hydrophilic polymers. A process of preparation of an extended release formulation, which comprises i) mixing the active agent, hydrophilic polymers and optionall...
A process for the preparation of 4-[2-(Di-n-propylamino)ethyl]-2,3-dihydro-1H-indol-2-one of formula (I) and its pharmaceutically acceptable salts, solvates, involving new intermediates of compound of formula (A)and(B)
wherein R represents
(i)a halogen atom selected from fluorine, chlorine atom, bromine atom and i...
The invention relates to a modified release tablet of lamotrigine comprising: from about 5 to 30 % w/w of lamotrigine; from about 30 to 50 % w/w of a filler; from about 1 to 16 % w/w of a first release controlling polymer and from about 22 to 42 % w/w of a second release controlling polymer.
The present invention relates to an improved process for preparing 1-(pentanoylamino)cyclopentanecarboxylic acid formula (I) which is useful intermediate for the preparation of Irbesartan
The invention relates to an extended release tablet comprising an active core comprising ropinirole, a pH independent non-swelling release retardant, a hydrophilic cellulosic polymer and a viscosity-increasing agent; coated with one or more than one separate release control layers in which the release control layer/...
The present invention relates to an improved process for the preparation of carbamoyl chloride and chloroformate by treating gaseous phosgene with respective gaseous amine and gaseous alcohol in continuous short path reactor (CSPR).
This invention relates to an extended release pharmaceutical composition of quetiapine or a pharmaceutically acceptable salt thereof and to a process for preparation of same. The extended release pharmaceutical compositions of present invention is useful in providing therapeutically effective levels of quetiapine or...
The present invention provides an improved process for the preparation of Linezolid of formula (I) and (R)-N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methanol of formula (II) which is a key intermediate for the preparation of Linezolid of formula (I).
The present invention relates to provide an improved process for preparation of Pentosan polysulfate of formula (1) or salt thereof, comprising a step of treating xylan with chlorosuifonic acid in the presence of picoline.
The present invention relates to process for the preparation of 6-O-methylerythromycin A of formula (I) via selective methylation of hydroxy group at the 6 position of erythromycin A derivative.
The present invention relates to a novel crystalline form of hexamethylenediamine salt of Montelukast. It also relates to a process for the preparation of hexamethylenediamine salt of Montelukast and its use for the preparation of Montelukast Sodium.
The present invention provides a new polymorph Form I of Teriflunomide sodium and a process for preparation thereof. The present invention provides an amorphous form of Teriflunomide sodium and a process for preparation thereof. The present invention provides a new polymorph Form I of Teriflunomide potassium and a p...
The present invention relates to an improved process for preparing Bupropion Hydrochloride of formula (I). The present invention also provides a process for purification of Bupropion hydrochloride.
The present invention provides novel process for the preparation of Topiramate Form I which comprising purifying crude Topiramate base by treating the same with mixture of acetone and water to obtain topiramate of at least 99.5% purity.
The present invention relates to stable pharmaceutical composition comprising valsartan or pharmaceutically acceptable salts thereof and amlodipine or pharmaceutically acceptable salts thereof optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparing such compos...
The invention relates to an extended release formulation comprising hard gelatin capsule containing a therapeutically effective amount of mini-tablets comprised of venlafaxine hydrochloride, binder, diluent and coating comprising of water soluble polymer and water insoluble component which reseases the venlafaxine h...
The present invention provides an improved process for the purification of Ropinirole hydrochloride of formula (Ia) comprising steps of: (i) treating Ropinirole hydrochloride with sodium dithionate and charcoal in suitable alcoholic solvent; (ii) triturating Ropinirole hydrochloride obtained in step (i) with ethanol...
The present invention relates to an improved process for the preparation of (E)-N, N-diethyl-2-cyano-3- (3,4-dihydroxy-5-nitrophenyl) acrylamide formula (I) comprising steps of, (a) condensation of 3, 4-dihydroxy-5- nitrobenzaldehyde of formula (II)
with N, N-diethylcyanoacetamide of formula (III) in the presence ...
The present invention relates to a process for the separation and detection of Penicillin traces.
The present invention relates to a process for preparing 1-(4-hydrazinophenyl) methyl-1, 2, 4-triazole (VI) which is key intermediate in the preparation of Rizatriptan benzoate.
The present invention relates to an improved process for the preparation of carbamoyl chloride and chloroformate by treating gaseous phosgene with respective gaseous amine and gaseous alcohol in continuous short path reactor (CSPR).
The present invention relates to novel crystalline polymorphic form of O-desmethyl venlafaxine which is designated as form A and process for the preparation of the same.
The present invention relates to the process for the preparation of compounds of formula (I) or its pharmaceutically acceptable salts wherein R is
Process for purification of (S)-N-(l-Carboxy-2-methvl-prop-l-yO-N-pentanoyl-N-[2"-(lH-tetrazol-5-yl)biphenyl-4-ylmethyl -amine
The present invention relates to process for purification of (S)-N-(l-Carboxy-2-methyl-prop-l-yl)-N-pentanoyl-N-[2"-(lH-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine.
The present invention relates to an improved method for producing a 4-{sub.-2- pyridy1) ethoxy}nitrobenzene compound of formula (II),wherein R1 is selected from group of -H,C1-6 alkyl or C1-6 acyl, substantially free from impurity of formula(v).
Present invention relates to an improved process for preparation of Levetiracetam of formula (I).
A method of testing the purity of a sample of Telithromycin or a pharmaceutical dosage form comprising Telithromycin, which method comprises assaying the said sample for the presences of compound A, B and D. Where in compound A is represented by following structural formula; Compound B is represented by following st...
A low-calorie solid, pourable composition for emulating sugar, the composition comprising an intense sweetener and at least one low-calorie bulking agent selected from maltodextrin, magnesium oxide, magnesium carbonate, calcium stearate, colloidal silicon dioxide and starch or combinations thereof, and a process for...
The present invention relates to the process for the preparation of Erythromycin A (I) substantially free of Erythromycin B (III) by treating Erythromycin thiocyanate with ammonia in halogenated solvent. Also Erythromycin A oxime (II) is prepared.
The present invention relates to delayed release formulation of choline fenofibrate. More particularly, the present invention relates to a formulation for controlling the release of choline fenofibrate by applying at least one release rate controlling coating layer and at least one enteric coating layer.
...
The present invention relates to process for preparation of tetrazoles of formula (I) from aromatic cyano derivatives of formula (II) comprising of treating the cyano compound of formula (II) with trialkyltin halide and metal azide in presence of base.
The present invention relates to process for the preparation of 6-O-methylerythromycin A 9-oxime by treating 6-O-methylerythromycin A with hydroxyl amine hydrochloride in the presence of a base and a solvent.
The present invention relates to an improved process for preparation of azetidine-3-carboxylic Acid represented by a structural formula (I) as given below.
The present invention relates to cost efficient process for preparation of sucralose. The present invention relates to recovery of the reagents from feed mixture obtained in various steps of sucralose. Particularly, the present invention relates to recovery of trityl chloride, ß-picoline, triphenylphosphine oxide (T...
An improved process for manufacture of l-[cyano (p-methoxyphenyl) methyl ] cyclohexanol of the structural formula given in Figure 1 which comprises reaction of 4-methoxyphenylacetonitrile with cyclohexanone characterized in that 4-methoxyphenylacetonitrile is reacted with cyclohexanone in the presence of alkali meta...
The present invention relates to an extended release pharmaceutical composition comprising levetiracetam. In particular, the present invention relates to a novel coated extended release pharmaceutical composition comprising levetiracetam.
The present invention relates to an improved process for preparing Losartan Potassium of formula (I).
Present invention relates to an improved process for the preparation of Praziquantel of formula (I).
The present invention relates to a process for the preparation of Venlafaxine Hydrochloride comprising steps of i) treating 4-methoxyphenyl acetonitrile with cyclohexanone in presence of alkali hydroxide and super base to get 1-[cyano (4-methoxyphenyl) methyl] cyclohexanol and ii) reducing 1-[cyano (4-methoxyphenyl)...
The present invention relates to provide an improved process for the preparation of tolterodine or salt thereof, comprises a step of reducing 3-(2-methoxy-5-methylphenyl)-3-phenyl propionic acid of formula (III) in the presence of a reducing agent, an acidic reagent and a solvent to obtain 3-(2-methoxy-5-methylpheny...
The present relates to provide an improved for the preparation of Clonidine hydrochloride comprising steps of:
(i) reacting 2,6-dichloroaniline with pivalic formic anhydride in the presence of solvent to obtain N-(2,6-dichlorophenyl) formamide
(ii) carrying out an one-pot reaction without isolating the intermediat...
The present invention relates to an improved process for the preparation of 2, 3, 6, 3’, 4’-penta-o-acetylsucrose(6-PAS) (V) and sucralose.
The present invention relates to an improved process for the preparation of 2, 3, 6, 3’, 4’-penta-o-acetylsucrose(6-PAS) (V) and sucralose (I).
The present invention relates to novel process for preparing Donepezil hydrochloride.
A process. For preparing a. controlled. release formulation, of macrolide such as erythromycin estolate comprising 50-85% by wt said macrolide 3 to 15% by wt polymers and pharmaceutically acceptable carriers such. as. osmotic agent, filler, lubricant and binder,, said process comprises the following steps:
a) pass...
The present invention provides an improved process for the preparation of Linezolid of formula (I) from Linezolid amine of formula (Ia) comprising acylation using acylating agent in the presence of ketonic solvent.
The present invention further provides process for the preparation of Form I of Linezol...
The present invention provides a process for preparing Teriflunomide.
The present invention relates to process for the preparation of Prasugrel HCl having formula (I).
The present invention relates to a novel process for the preparation of Alfuzosin hydrochloride of formula (I). It also provides novel intermediate off formula (IX) and its use for preparation of Alfuzosin hydrochloride of formula (I)
The present invention also relates to a process for the preparation of novel inte...
The present invention relates to a process for preparation of Losartan potassium Form I.
The present invention relates to a process for preparing highly pure Meprobamate of formula (I).
The present invention provides a process for preparation of amorphous form of Lercanidipine HCl.
The present invention relates to an improved process for preparing Bosentan of formula (I).
The present invention relates to an improved process for the preparation of Pentosan polysulfate of formula (I)
or salt thereof, wherein R represents -SO3Y, and Y is at least one member selected from the group consisting of H and a pharmaceutically acceptable cation such as sodium, potassium, and magnesium which...
The invention relates to process of preparing stable Azithromycin monohydrate of formula (I), by drying in air under humid conditions. It also discloses amorphous 9-deoxo-6-deoxy-6, 9-epoxy-9, 9a-didehydro-9a-aza-9a-homoerythromycin A of Formula (IV) and its process for preparation, which is an useful intermediate f...
The present invention relates to improved process for hydrolysis of N-[(2’-(1H-Tetrazol-5-yl)biphenyl-4-yl)methyl]-N-valeryl-(L)-valine ester derivative of formula (II), henceforth referred as “Valsartan ester derivative” , which is penultimate intermediate for the preparation of Valsartan of formula (I), chemically...
The present invention provides a novel process for preparation of bisphosphonic acid derivatives or pharmaceutical acceptable salt thereof, by reacting carboxylic acid having structural formula (II) with phosphorous acid and a halophoshorous compound, wherein halophosphorous compound is selected from the group compr...
Trans-[4-Isorpopyl cyclohexyl carboxylic acid] in dichloromethane was reacted with thionyl chloride at 25 -30 degree/C and then with mixture of phenylanine methyl ester hydrochloride and triethylamine. The contents after quenching in water were extracted in dichloromethane and intermediate product was isolated by ev...
The present invention relates to an improved process for preparation of Rivastigmine of formula (I) or pharmaceutically acceptable salts thereof comprising a step of N-methylation of compound of formula (III), wherein R1 = R2 = H or R1 = H and R2 = CH3 or an acid addition salt thereof, using paraformaldehyde in the ...
The present invention relates to the process for the preparation of compounds of formula (I) or its pharmaceutically acceptable salts wherein, R is
The present invention relates to pharmaceutical compositions comprising bupropion hydrochloride and a pharmaceutically acceptable stabilizer where the stabilizer used is a dextrin, a polyacid derivative or a mixture of both.
The present invention encompasses a process for the preparation of highly pure Ivabradine hydrochloride by treating crude Ivabradine with derivatizing agent which derivatize impurities adhered with the crude Ivabradine.
The present invention relates to an improved process for preparing Iloperidone of formula
(i).
A process for the preparation of substituted benzoyl Nitriles [I] prepared by the reaction of substituted benzoylchlorides with cuprous cyanide using alkali metal iodide in the presence of aromatic solvents having a boiling range between 150°C to 200°C. wherein R = H and halogens such as F...
The present invention relates to an improved, cost effective and easy process for the preparation of azithromycin monohydrate isopropanol clathrate. The process provides a one-step method of preparing azithromycin monohydrate isopropanol clathrate directly from 9-deoxo-9a-aza-9a-homoerythromycin A. The proce...
NOVEL POLYMORPHIC FORMS OF (S)-(-)-2-AMINO-6-(N-PROPYLAMINO)-4,5,6,7- TETRAHYDROBENZOTHIAZOLE
The present invention relates to novel polymorphic forms of (S)-(-)-2-Amino-6-(n-propylamino)-4,5,6,7-tetrahydrobenzothiazole designated as Form I, II, III and IV and its process for preparation.
16
...
Charges
08 May 2006
Bank Of Baroda & Other Banks
50 Crore
15 May 2007
Member Secretary
30 Lak
05 April 2007
Standard Chartered Bank
43 Crore
25 September 2009
Idbi Trusteeship Services Limited
25 Crore
13 September 2007
Idbi Trusteeship Services Ltd
75 Crore
11 August 2009
Idbi Trusteeship Services Limited
25 Crore
15 December 2006
Bnp Paribas
22 Crore
03 September 2004
Abn Amro Bank N.v.
23 Crore
09 November 2004
State Bank Of Indore
30 Crore
08 May 2003
Idbi Bank Limited
9 Crore
27 November 1998
Bank Of Baroda
41 Crore
17 October 1998
Abn-amro Bank N.v.
12 Crore
30 September 2000
Union Bank Of India
22 Crore
01 March 1999
Indian Bank
7 Crore
22 March 1996
Icici Bank Limited
19 Crore
01 March 1999
Axis Bank Limited
10 Crore
26 December 2003
State Bank Of India
40 Crore
09 December 2003
Co-operatieve Centrale Raiffeisen-boerenleenbank B A
18 Crore
09 July 2001
Bharat Overseas Bank Ltd
10 Crore
24 May 2004
Bank Of Bahrain And Kuwait B S C
12 Crore
22 September 2023
Others
0
08 May 2006
Others
0
15 May 2007
Member Secretary
0
13 September 2007
Idbi Trusteeship Services Ltd
0
11 August 2009
Idbi Trusteeship Services Limited
0
15 December 2006
Bnp Paribas
0
05 April 2007
Standard Chartered Bank
0
09 November 2004
State Bank Of Indore
0
03 September 2004
Abn Amro Bank N.v.
0
17 October 1998
Abn-amro Bank N.v.
0
08 May 2003
Idbi Bank Limited
0
27 November 1998
Bank Of Baroda
0
26 December 2003
State Bank Of India
0
01 March 1999
Indian Bank
0
01 March 1999
Axis Bank Limited
0
22 March 1996
Icici Bank Limited
0
09 December 2003
Co-operatieve Centrale Raiffeisen-boerenleenbank B A
0
24 May 2004
Bank Of Bahrain And Kuwait B S C
0
09 July 2001
Bharat Overseas Bank Ltd
0
30 September 2000
Union Bank Of India
0
25 September 2009
Idbi Trusteeship Services Limited
0
22 September 2023
Others
0
08 May 2006
Others
0
15 May 2007
Member Secretary
0
13 September 2007
Idbi Trusteeship Services Ltd
0
11 August 2009
Idbi Trusteeship Services Limited
0
15 December 2006
Bnp Paribas
0
05 April 2007
Standard Chartered Bank
0
09 November 2004
State Bank Of Indore
0
03 September 2004
Abn Amro Bank N.v.
0
17 October 1998
Abn-amro Bank N.v.
0
08 May 2003
Idbi Bank Limited
0
27 November 1998
Bank Of Baroda
0
26 December 2003
State Bank Of India
0
01 March 1999
Indian Bank
0
01 March 1999
Axis Bank Limited
0
22 March 1996
Icici Bank Limited
0
09 December 2003
Co-operatieve Centrale Raiffeisen-boerenleenbank B A
0
24 May 2004
Bank Of Bahrain And Kuwait B S C
0
09 July 2001
Bharat Overseas Bank Ltd
0
30 September 2000
Union Bank Of India
0
25 September 2009
Idbi Trusteeship Services Limited
0
Documents
Optional Attachment-(1)-26032024
Form Addendum to AOC-4 CSR-26032024_signed
Optional Attachment-(1)-04102023
Optional Attachment-(2)-04102023
AleltdMGT7AnnualReturn_F65687782_CSKEVAL91_20231004184631.xls
Optional Attachment-(4)-04102023
Copy of MGT-8-04102023
Optional Attachment-(3)-04102023
Form MGT-7-04102023_signed
XBRL document in respect Consolidated financial statement-07092023
Statement of subsidiaries as per section 129-Form AOC-1 (To be attached in respect of Foreign subsidiaries)-07092023
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-07092023
Optional Attachment-(1)-07092023
Form AOC-4(XBRL)-07092023_signed
Form MGT-15-03092023_signed
Form Addendum to AOC-4 CSR-01092023_signed
Form MGT-15-22082023_signed
Optional Attachment-(1)-21082023
Optional Attachment-(1)-28032023
Form Addendum to AOC-4 CSR-28032023
Optional Attachment-(1)-21102022
Optional Attachment-(2)-21102022
Alembic_Limited-MGT_7_List_of_F32238586_DRIGESH1_20221027120606.xls
Copy of MGT-8-21102022
Form MGT-7-21102022
Form AOC-4(XBRL)-19102022_signed
Statement of subsidiaries as per section 129-Form AOC-1 (To be attached in respect of Foreign subsidiaries)-14102022
XBRL document in respect Consolidated financial statement-14102022
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-14102022
Optional Attachment-(1)-10102022
